Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Mikel Etchegaray"'
Autor:
Kathryn A. Lai, Ajay Sheshadri, Andres M. Adrianza, Mikel Etchegaray, Diwakar D. Balachandran, Lara Bashoura, Vickie R. Shannon, Saadia A. Faiz
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Pp 172-174 (2020)
Introduction: Since immune checkpoint inhibitor (ICI) blockade has become standard therapy for many cancers, immune-related adverse events (irAEs) have increased. ICI-pneumonitis is infrequent but potentially fatal. In cases not responsive to cortico
Externí odkaz:
https://doaj.org/article/1342f7d3d8e340e8bd2d925f5a818b99
Autor:
Nikeshan Jeyakumar, Mikel Etchegaray, Jason Henry, Laura Lelenwa, Bihong Zhao, Ana Segura, L. Maximilian Buja
Publikováno v:
Case Reports in Immunology, Vol 2020 (2020)
Background. We report a case of a patient with squamous cell carcinoma (SCC) who developed myasthenia gravis (MG), myositis, and myocarditis after receiving cemiplimab, an anti-PD-1 immune checkpoint inhibitor (ICI). Case Presentation. An 86-year-old
Externí odkaz:
https://doaj.org/article/8023f363092c412e981dbf26eb7c578b
Autor:
Joanna-Grace M. Manzano, Mayoora Muthu, Ed Kheder, Alyssa Mohammed, Josiah Halm, Kodwo Dickson, Noman Ali, Cerena Leung, Kwame Koom-Dadzie, David Rubio, Orhue Odaro, Michelle Sibille, Mikel Etchegaray, Kaycee Wilson, Heather Lin, Marina George
Publikováno v:
Supportive Care in Cancer. 30:7783-7788
Several studies have confirmed increased mortality among patients with both COVID-19 and cancer. It remains important to continue to report observations of morbidity and mortality from COVID-19 in this vulnerable population. The purpose of this study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62031162272c054f0b5dbc900dd535ae
https://doi.org/10.1007/s00520-022-07209-w
https://doi.org/10.1007/s00520-022-07209-w
Autor:
Andres M. Adrianza, Diwakar D. Balachandran, Lara Bashoura, Saadia A. Faiz, Vickie R. Shannon, Kathryn A. Lai, Mikel Etchegaray, Ajay Sheshadri
Publikováno v:
J Immunother Precis Oncol
IntroductionSince immune checkpoint inhibitor (ICI) blockade has become standard therapy for many cancers, immune-related adverse events (irAEs) have increased. ICI-pneumonitis is infrequent but potentially fatal. In cases not responsive to corticost
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc13815adf8dc6c3e4819f97b542d863
https://europepmc.org/articles/PMC9165439/
https://europepmc.org/articles/PMC9165439/
Autor:
Jason Henry, Mikel Etchegaray, Bihong Zhao, Ana Maria Segura, Laura Lelenwa, L. Maximilian Buja, Nikeshan Jeyakumar
Publikováno v:
Case Reports in Immunology, Vol 2020 (2020)
Case Reports in Immunology
Case Reports in Immunology
Background. We report a case of a patient with squamous cell carcinoma (SCC) who developed myasthenia gravis (MG), myositis, and myocarditis after receiving cemiplimab, an anti-PD-1 immune checkpoint inhibitor (ICI). Case Presentation. An 86-year-old
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6c913bcc3eb21db595f3ae8cebd9e6e
https://doaj.org/article/8023f363092c412e981dbf26eb7c578b
https://doaj.org/article/8023f363092c412e981dbf26eb7c578b
Publikováno v:
Endocrine Practice. 25:7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::879a4d28671f0d0ca9540c5371d5ebef
https://doi.org/10.1016/s1530-891x(20)46454-7
https://doi.org/10.1016/s1530-891x(20)46454-7